Home
Clinical Trials
Efficacy and Safety of Berber...

Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis

NCT ID: NCT03198572

Last Updated: 2023-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-16

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of berberine treatment on Non-alcoholic Steatohepatitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT04049396

Non-Alcoholic Fatty Liver Disease

COMPLETED NA

Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults

NCT03972631

Non-Alcoholic Fatty Liver Disease Obesity

UNKNOWN NA

Fatty Liver Disease Collaborative Research in China

NCT02391168

Fatty Liver Fatty Liver, Alcoholic Non-alcoholic Fatty Liver Disease

UNKNOWN

Treatment of NAFLD With Two Different Diets

NCT03118310

NAFLD

COMPLETED PHASE2

Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)

NCT01418027

Non-alcoholic Fatty Liver Disease (NAFLD)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to investigate the efficacy and safety of berberine on subjects with Non-alcoholic Steatohepatitis.Patients with biopsy-proven non-alcoholic steatohepatitis (NASH) from 18-65 years of age were enrolled. Patients should had no excessive alcohol intake or use of any hepatoprotective or hepatotoxicity medication within 3 months before enrollment.Patients will have an screening period 12 weeks, and a 48-week double-blinded treatment period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Berberine

Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.

Group Type EXPERIMENTAL

Lifestyle intervention

Intervention Type BEHAVIORAL

Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.

Berberine

Intervention Type DRUG

Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks

Placebo

Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.

Group Type PLACEBO_COMPARATOR

Lifestyle intervention

Intervention Type BEHAVIORAL

Placebo

Intervention Type DRUG

placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lifestyle intervention

Intervention Type BEHAVIORAL

Placebo

placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks

Intervention Type DRUG

Berberine

Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-75 years old, no limitation for ethnicity and gender.
2. BMI is no more than 40 kg/m2.
3. Patients with NASH based on liver biopsy obtained within 24 weeks before randomization. The histological evidence of NASH is defined as NAS ≥5 \[\] or NAS ≥4 with a minimum score of 1 for all of three components (steatosis, hepatocyte ballooning, and lobular inflammation), the diagnosis of NASH for EASYBEinNASH eligibility is based on reviews by three pathologists. If there are controversial pathologic diagnosis, at least 2 of the 3 pathologists are consistent with the pathologic diagnosis, which will be the final pathological diagnosis. If there are three different pathological diagnoses, it needs to be discussed and make a judgment by the chief pathologist to form the final pathology report.
4. For patients with impaired glucose metabolism, one of the three following conditions needs to be met.

① For patients diagnosed as impaired glucose regulation, they will be treated with lifestyle intervention without hypoglycemic drugs;

② For patients diagnosed as diabetes and treated with hypoglycemic drugs, the treatment regimen should not be changed and the dosage should remain stable for more than 2 months before randomization;

③ For patients diagnosed as diabetes and treated with lifestyle intervention without hypoglycemic drugs, the treatment regimen should not be changed before randomization.
5. All participants agree to sign the informed consent form.

Exclusion Criteria

1. Excessive alcohol intake ( \> 140 g per week for men and \>70 g per week for women within 6 months before enrollment);
2. Liver enzymes (ALT or aspartate aminotransferase(AST) is 5 times higher than the upper limit of normal range;
3. Liver diseases caused by other reasons, such as alcohol abuse, viral hepatitis, drugs, auto-immune hepatitis, hereditary liver disease, liver cirrhosis, liver cancer, etc;
4. Biliary tract diseases, biliary obstructive disease, etc;
5. Other diseases that affect glucose and lipid metabolism, such as hypothyroidism, hyperthyroidism, hypercortisolism, etc;
6. Diabetic patients with poor blood glucose control: HbA1c \>9.5%;
7. Use of drugs that may affect the outcome measures of this study 3 months before enrollment, including pioglitazone, GLP-1 receptor agonist, DPP-4 inhibitor, insulin, and glycyrrhizic acid preparation, etc;
8. Chronic kidney disease or severe renal impairment, defined as serum creatinine greater than 2.0mg/dL (176.8umol/L);
9. Life expectancy is no more than 5 years;
10. Pregnant or planning to become pregnant within the next 64 weeks for female participant;
11. Any situation that may affect the implementation or results of the study;
12. Continuous use of drugs that may affect steatohepatitis 3 months before enrollment, such as glucocorticoids, methotrexate, etc;
13. Subjects participated in other clinical trials in the past 4 weeks; The researchers did not think they were suitable for the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xin Gao

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xin Gao

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.